Tecan schedules conference call on March 14 to discuss Full-Year 2022 Financial Results
Männedorf, Switzerland, March 7, 2023 – The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media conference call to discuss the full-year 2022 financial results on Tuesday, March 14, 2023 at 09:00 am CET. The press release with the 2022 full-year financial results and the Annual Report 2022 will be published on March 14, 2023 at 6:30 am CET.
The conference call will be audio-webcast with synchronized presentation slides. A link to the webcast will be made available in the "Investor Relations" section of Tecan's website www.tecan.com immediately prior to the event.
Interested parties can also listen to the conference by phone.
The dial-in numbers for the call are as follows:
Participants from Europe: +41 58 310 50 00 or +44 207 107 0613 (UK)
Participants from the U.S.: +1 631 570 5613
Participants should if possible dial in 15 minutes before the start of the event.
A replay of the webcast will be available after the presentation on the website www.tecan.com for a period of 90 days
About Tecan
Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2021, Tecan generated sales of CHF 947 million (USD 1,041 million; EUR 877 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.29.3.2023 22:02:33 CEST | Press release
March 29, 2023 Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA,MVA, MSN, FACHEand other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. COPENHAGEN, DENMARK and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces that Chris Lindop, Chairman of the Board of Directors, has for personal reasons decided not to stand for re-election at the upcoming ordinary general meeting. The Board plans to appoint current Vice Chairman, John McDonough, as the new Chairman following the AGM on April 27, 2023. “I am proud to have helped shepherd BioPorto through this period of significant change and opportunity,” said Mr. Lindop. “I am very confident in the Board, Management, and entire team as they commercialize NGAL tests for Acute Kidney Injury (AKI) in Europe and pursue approval of the first authorized AKI biomarker in the US.” The Board also announces that
Inventiva reports its 2022 full-year results29.3.2023 22:00:00 CEST | Press release
Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 Inventiva entered into a license and collaboration agreement with Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ, to develop, manufacture and commercialize lanifibranor in Greater China Under this agreement with Sino Biopharm, Inventiva received a €12.8 million¹ upfront payment Inventiva received the first tranche of €25 million under its credit facility with the European Investment Bank (EIB) Screening of the first patients in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D Secured a new patent expanding the IP protection of lanifibranor in the U.S. In January 2023, Inventiva announced changes to NATiV3, a Phase III trial with lanifibranor in patients with NASH, that are expected to be beneficial to the clinical program Daix (F
Nova Klúbburinn hf.: Niðurstöður aðalfundar þann 29. mars 202329.3.2023 21:54:28 CEST | Press release
Aðalfundur Nova Klúbbsins hf. var haldinn í dag, miðvikudaginn, 29. mars 2023. Þetta var fyrsti aðalfundur í skráðu félagi sem eingöngu var stýrt af konum en Hrund Rudolfsdóttir flutti skýrslu stjórnar, Margrét Tryggvadóttir skemmtana- & forstjóri fór yfir árið, Svanhildur Magnúsdóttir var fundarstjóri og ritari fundar var Ásta Guðjónsdóttir. Í stjórn félagsins voru kjörnir eftirfarandi einstaklingar: Hrund Rudolfsdóttir Jón Óttar Birgisson Jóhannes Þorsteinsson Magnús Árnason Sigríður Olgeirsdóttir Jóhannes, Sigríður og Magnús koma inn í stjórnina í stað Hugh Short, Kevin Payne og Tinu Pidgeon. Stjórn hefur skipt með sér verkum og var Sigríður Olgeirsdóttir kjörinn formaður stjórnar. Jóhannes Þorsteinsson starfar í dag sem yfirmaður fjárstýringar T-Mobile í Bandaríkjunum, þar sem hann ber ábyrgð á allri fjármögnun fyrirtækisins. T-Mobile er leiðandi fyrirtæki á fjarskiptamarkaði í Ameríku. Sigríður Olgeirsdóttir er reyndur stjórnandi í hugbúnaðar- og hátæknigeiranum. Magnús er sjálfst
Orkuveita Reykjavíkur – Green Bond Offering Results29.3.2023 20:44:54 CEST | Press release
Today, March 30th, Orkuveita Reykjavíkur (OR; Reykjavik Energy) concluded a closed green bond offering in series OR020934 GB and OR180255 GB. OR020934 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of September 2nd, 2034. Previously, bonds have been issued with a nominal value of ISK 12,617 million in the category. The series attracted bids totalling ISK 2,160 million nominal value at yields between 3.17% and 3.35%. OR accepted bids amounting to ISK 1,960 million at a yield of 3.24%. OR180255 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of February 18th, 2055. Previously, bonds have been issued with a nominal value of ISK 22,601 million in the category. The series attracted bids totalling ISK 820 million nominal value at yields between 2.99% and 3.15%. OR accepted bids amounting to ISK 620 million at a yield of 3.04%. Fossar Investment Bank oversees the issuance and sale of the b
Medium-term Fiscal Strategy Plan 2024-2028: to counter inflation, safeguard living standards and support growth29.3.2023 20:11:00 CEST | Press release
The government's fiscal strategy plan for the next five years lays out its strategy to utilise fiscal policy in a targeted manner to counter inflation and overheating by increasing expenditure restraint and revenue generation and postponing public investments. At the same time, important basic services that the government has significantly reinforced in recent years are maintained, based on the strong position of the Treasury. Financial support will be provided for those groups least able to withstand the impact of rising inflation, as was done with the government's support actions during the pandemic and the previous year. The Treasury’s fiscal position has improved significantly in recent quarters , and the fiscal outlook for this year appears likely to be better than implied by the most optimistic scenarios of previous projections. Eighteen months ago, the objective was set in the government’s Fiscal policy statement to halt the increase in debt to GDP ratio no later than by year-en